Stocks Health care HIMS
NYSE · Health careHims & Hers Health, Inc. (HIMS)
Hims & Hers Health, Inc. brought in $2.9B of revenue over the twelve months to September 30, 2026, up 29.8% from a year earlier. It posted a net loss of $190.8M. Operating cash flow minus capital spending left $57.4M of free cash flow in fiscal 2025. At September 30, 2026 it held $605.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Hims & Hers Health, Inc.
- Net worth
- Hims & Hers Health, Inc. has a market value (market cap) of $4.5B at the latest share price, and shareholders' equity of $355.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $2.3B (+59.0% year on year), with net income of $128.4M. Over the 12 months to September 30, 2026: revenue $2.9B, net loss $190.8M.
- Cash flow
- In fiscal 2025 operations brought in $300M of cash; after $242.6M of capital spending, free cash flow was $57.4M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Hims & Hers Health, Inc.'s next report is expected around February 22, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Hims & Hers Health, Inc. does
Hims & Hers Health, Inc. is registered with the SEC under industry code SIC 8011 (Services-Offices & Clinics of Doctors of Medicine). Its shares trade on NYSE under the ticker HIMS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2.3B | $128.4M | $0.51 | $57.4M |
| 2024 | $1.5B | $126M | $0.53 | $198.3M |
| 2023 | $872M | -$23.5M | -$0.11 | $47M |
| 2022 | $526.9M | -$65.7M | -$0.32 | -$33.7M |
| 2021 | $271.9M | -$107.7M | -$0.58 | n/a |
| 2020 | $148.8M | -$18.1M | -$0.51 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where HIMS ranks in Health care
Latest SEC filings
What Hims & Hers Health, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 49% to $890.4M versus the same quarter last year; diluted EPS -$0.14 versus $0.06.
- November 9, 2026
- November 9, 2026
- October 30, 2026Passive stake changed SCHEDULE 13G/A
- October 7, 2026Executive or director change8-KHims & Hers Health appointed Jonathan M. Franklin as chief accounting officer and principal accounting officer.
- August 31, 2026Activist stake changed SCHEDULE 13D/A
- August 10, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 38% to $753.2M versus the same quarter last year; diluted EPS -$0.37 versus $0.17.
- August 10, 2026
- July 31, 2026Passive stake (5% or more) SCHEDULE 13G
- July 28, 2026Passive stake changed SCHEDULE 13G/A
What is HIMS worth? A DCF from its reported cash flow
Insider trades
What the people running Hims & Hers Health, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $4.1M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 28, 2026 | Boughton SoleilChief Legal Officer | Soldpre-planned (10b5-1) | 3,462 | $95.6K |
| October 14, 2026 | Boughton SoleilChief Legal Officer | Soldpre-planned (10b5-1) | 3,461 | $100.6K |
| October 1, 2026 | Okupe OluyemiChief Financial Officer | Soldpre-planned (10b5-1) | 2,000 | $59.4K |
| September 30, 2026 | Boughton SoleilChief Legal Officer | Soldpre-planned (10b5-1) | 3,461 | $101K |
| September 22, 2026 | Okupe OluyemiChief Financial Officer | Exercised options | 14,000 | $70.1K |
| September 22, 2026 | Okupe OluyemiChief Financial Officer | Soldpre-planned (10b5-1) | 29,277 | $876.8K |
| September 17, 2026 | Okupe OluyemiChief Financial Officer | Soldpre-planned (10b5-1) | 12,313 | $354.9K |
| September 16, 2026 | Boughton SoleilChief Legal Officer | Soldpre-planned (10b5-1) | 6,236 | $173.7K |
Who owns HIMS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Andrew Dudum13D, may seek influence | 9.4% | August 31, 2026 |
| G1 Execution Services, LLC13G, passive with 3 related filers | 6.5% | May 15, 2026 |
| Vanguard Capital Management13G, passive | 5.01% | July 31, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 506 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 28,703,514 | +2,366,356 |
| Vanguard Portfolio Management LLC | 10,559,314 | +375,501 |
| Vanguard Capital Management LLC | 9,541,384 | +201,673 |
| State Street Corp | 8,145,699 | +685,676 |
| Morgan Stanley | 7,152,498 | -1,736,590 |
| Divisadero Street Capital Management, LP | 6,009,505 | +5,539,672 |
| Geode Capital Management, LLC | 5,681,832 | +483,053 |
| Goldman Sachs Group Inc | 5,173,865 | +2,719,170 |
| Jpmorgan Chase & Co | 4,766,781 | -474,035 |
| Fmr LLC | 4,323,292 | +4,230,022 |
| Marshall Wace, Llp | 4,217,767 | +3,493,540 |
| UBS Group AG | 2,660,810 | -1,490,828 |
| Northern Trust Corp | 2,594,277 | +158,248 |
| Charles Schwab Investment Management Inc | 2,453,787 | +95,073 |
| State of Michigan Retirement System | 2,346,282 | +7,682 |
| Bank of America Corp | 2,312,272 | -2,045,400 |
| Principal Financial Group Inc | 1,667,073 | +384,807 |
| Vanguard Fiduciary Trust Co | 1,522,249 | +72,864 |
| Bank of New York Mellon Corp | 1,333,146 | -7,300 |
| Cantor Fitzgerald, L. P. | 1,107,376 | +17,756 |
Insiders
15 insiders reported holding 3,104,614 shares in total, about $59.4M at the last price.
| Holder | Shares |
|---|---|
| Dudum AndrewChief Executive Officer, Director, 10% owner | 1,136,583103,406 held indirectly |
| Chi MichaelChief Operating Officer | 456,660 |
| Boughton SoleilChief Legal Officer | 293,886 |
| Okupe OluyemiChief Financial Officer | 234,527 |
| Wells David BDirector | 229,808 |
| Carroll Patrick HarrisonChief Medical Officer | 197,847 |
| Elshenawy MohamedCTO | 185,556 |
| Perez Garcia Andrea GDirector | 83,822 |
| Cosgrove Delos M.Director | 67,995 |
| Pendarvis ChristianeDirector | 55,430 |
Questions about HIMS
What does Hims & Hers Health, Inc. do?
Hims & Hers Health, Inc. is a company in the Health care sector, listed on NYSE as HIMS. Its shares trade on NYSE under the ticker HIMS.
What is Hims & Hers Health, Inc.'s net worth?
Hims & Hers Health, Inc. has a market value (market cap) of $4.5B at the latest share price, and shareholders' equity of $355.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Hims & Hers Health, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $190.8M on revenue of $2.9B.
How much revenue does Hims & Hers Health, Inc. make?
Over the twelve months to September 30, 2026 Hims & Hers Health, Inc. reported revenue of $2.9B. That is 29.8% more than a year earlier.
When did Hims & Hers Health, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Hims & Hers Health, Inc.'s next earnings report?
Hims & Hers Health, Inc.'s next report is expected around February 22, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare HIMS with
Follow HIMS
Get an email when Hims & Hers Health, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Hims & Hers Health, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.